These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
770 related articles for article (PubMed ID: 34593465)
1. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465 [TBL] [Abstract][Full Text] [Related]
2. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501 [TBL] [Abstract][Full Text] [Related]
3. Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs. Chen HY; Chen CH; Liao WC; Lin YC; Chen HJ; Hsia TC; Cheng WC; Tu CY BMC Pulm Med; 2024 Oct; 24(1):517. PubMed ID: 39415161 [TBL] [Abstract][Full Text] [Related]
4. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085 [TBL] [Abstract][Full Text] [Related]
5. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
6. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
7. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related]
8. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468 [TBL] [Abstract][Full Text] [Related]
9. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
10. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539 [TBL] [Abstract][Full Text] [Related]
11. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. Yamamoto N; Mera T; Märten A; Hochmair MJ Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283 [TBL] [Abstract][Full Text] [Related]
12. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC. Pang L; Huang Y; Zhuang W; Zhang Y; Liao J; Hao Y; Hao F; Wang G; Chen ZC; Zhu Y; Li M; Song Z; Deng BP; Li J; Zhang L; Fang W Clin Cancer Res; 2024 Jun; 30(12):2636-2646. PubMed ID: 38578683 [TBL] [Abstract][Full Text] [Related]
13. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441 [TBL] [Abstract][Full Text] [Related]
14. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment. Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336 [TBL] [Abstract][Full Text] [Related]
15. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. Minari R; Leonetti A; Gnetti L; Zielli T; Ventura L; Bottarelli L; Lagrasta C; La Monica S; Petronini PG; Alfieri R; Tiseo M Anticancer Drugs; 2021 Aug; 32(7):758-762. PubMed ID: 33675607 [TBL] [Abstract][Full Text] [Related]
16. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report. Liu J; Jin B; Su H; Qu X; Liu Y BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676 [TBL] [Abstract][Full Text] [Related]
17. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T; Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616 [TBL] [Abstract][Full Text] [Related]
18. Overall Survival with Osimertinib in Untreated, Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC; N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012 [TBL] [Abstract][Full Text] [Related]
19. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib? Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922 [TBL] [Abstract][Full Text] [Related]
20. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. Auliac JB; Saboundji K; Andre M; Madelaine J; Quere G; Masson P; Vergnenegre A; Lamy R; Raymond S; Chiappa AM; Hauss PA; Fournel P; Corre R; Chouaid C Target Oncol; 2019 Jun; 14(3):307-314. PubMed ID: 31119481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]